Isis' partnership strategy has enabled the Company to build a broad product pipeline and to create an annuity of milestone payments and royalty revenues while limiting development expenses. This strategy enables the Company to remain focused on research and development and to discover new drugs and expand Isis' and Isis' partners pipelines. Please check here for updates on news, event participation and important scientific publications from our partners.

News
2008-07-14	OncoGenex Receives Completed Special Protocol Assessment for Primary Registration Study of Lead Drug Candidate OGX-011
2008-07-08	Atlantic Healthcare Receives Orphan Drug Designation for Alicaforsen for the Treatment of Pouchitis
2008-07-03	OncoGenex Increases Economic Interest in Lead Cancer Drug OGX-011
2008-06-30	Teva & ANP Announce that ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction in Disease Activity
2008-06-02	OncoGenex reports that low serum clusterin levels were predictive of survival in preliminary analyses of Phase 2 study of lead drug candidate OGX-011
2008-05-16	OncoGenex Reports Updated Survival Data on OGX-011 in a Second-Line Chemotherapy Trial for Patients with Prostate Cancer
2008-04-17	ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial
2008-02-11	Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd